Clinical Trials Browser

pertuzumab × NET × Clear all

NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Phase 2 Terminated

4 enrolled 5 charts

CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors